MX2019005572A - Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica. - Google Patents

Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.

Info

Publication number
MX2019005572A
MX2019005572A MX2019005572A MX2019005572A MX2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A
Authority
MX
Mexico
Prior art keywords
diabetes
treating type
medicinal complex
diabetic dyslipidemia
medicinal
Prior art date
Application number
MX2019005572A
Other languages
English (en)
Inventor
Sook Park Ki
Jin Yoon Hye
Hyuk Jung Jong
Won Kim Sung
Yoon Kim Ji
Cheol Yoo Seok
Sun Kim Ri
Soon Ahn Jae
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2019005572A publication Critical patent/MX2019005572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se relaciona a un complejo medicinal para tratar efectivamente diabetes tipo 2 y dislipidemia de pacientes diabéticos, más específicamente, la presente invención proporciona un complejo medicinal que comprende un inhibidor de peptidasa IV, gemigliptin o una sal farmacéuticamente aceptable del mismo, y un inhibidor de HMG-CoA reductasa, rosuvastatina o una sal farmacéuticamente aceptable del mismo, para controlar efectivamente los niveles de azúcar en la sangre y mejorar factores de riesgo de la enfermedad cardiovascular.
MX2019005572A 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica. MX2019005572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (ko) 2016-11-15 2017-11-15 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Publications (1)

Publication Number Publication Date
MX2019005572A true MX2019005572A (es) 2019-08-14

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005572A MX2019005572A (es) 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.

Country Status (9)

Country Link
KR (1) KR102055894B1 (es)
CN (1) CN109996545A (es)
BR (1) BR112019009709A2 (es)
CO (1) CO2019005207A2 (es)
MX (1) MX2019005572A (es)
PE (1) PE20191502A1 (es)
PH (1) PH12019501028A1 (es)
RU (1) RU2721406C1 (es)
WO (1) WO2018093144A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7553861B2 (en) * 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
WO2011018185A2 (en) * 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566465A2 (en) * 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
CN104473929B (zh) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 一种西格列汀辛伐他汀缓释组合物

Also Published As

Publication number Publication date
KR20180054500A (ko) 2018-05-24
BR112019009709A2 (pt) 2019-08-13
PE20191502A1 (es) 2019-10-22
WO2018093144A1 (ko) 2018-05-24
RU2721406C1 (ru) 2020-05-19
CN109996545A (zh) 2019-07-09
KR102055894B1 (ko) 2019-12-13
CO2019005207A2 (es) 2019-08-20
PH12019501028A1 (en) 2020-01-20

Similar Documents

Publication Publication Date Title
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
EP3589628A4 (en) ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
PH12015500434B1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
WO2012099448A3 (ko) αΑ-크리스탈린 유전자를 발현하는 재조합 아데노바이러스 및 이를 이용한 망막혈관 질환의 유전자 치료
WO2015022530A3 (en) Materials and methods relating to pancreatic cancer
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
PH12020500295A1 (en) Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
MX2019014988A (es) Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.
EP3669880A4 (en) USE OF miR-18b IN THE PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE AND NEUROMUSCULAR DISEASE
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity